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Small mammals have the ability to enter torpor, a hypothermic, hypometabolic state, allowing impressive energy conservation. Administration of adenosine or adenosine 5'-monophosphate (AMP) can trigger a hypothermic, torpor-like state. We investigated the mechanisms for hypothermia using telemetric monitoring of body temperature in wild type and receptor knock out (Adora1 À/À , Adora3 À/À ) mice.
Introduction
Mammals are endotherms, typically maintaining a warm core body temperature (Tb) of~35 C to 37 C, depending on circadian fluctuations (Refinetti, 2010) . Some small mammals, including mice, when exposed to an inadequate food supply in a quiet, cool environment use torpor to achieve significant energy conservation (Geiser, 2004; Melvin and Andrews, 2009) . Torpor is an example of a regulated hypothermia (anapyrexia), which is characterized by a reduced Tb set point, metabolic rate, and physical activity, with Tb falling close to the environmental temperature. In regulated hypothermia multiple physiologic mechanisms are coordinated to cool the body, including vasodilation, decreased physical activity, reduced brown adipose tissue thermogenesis, and seeking a cool environment (Lute et al., 2014) . Regulated hypothermia differs from hypothermia caused by cold exposure, where the body attempts, but is unable, to maintain Tb.
Hypothermia can also be caused by a wide variety of drugs and neurotransmitters (Clark and Lipton, 1985) , although in most cases it is not documented if there is a reduction in Tb set point. Clinically, hypothermia is routinely employed to minimize tissue damage after hypoxic or ischemic injury (Arrich et al., 2012; Azzopardi et al., 2014) . The hypothermia is typically induced with surface cooling. However, pharmacological reduction of the Tb might minimize undesired compensatory mechanisms (e.g., sympathetic activation, shivering). Development of a drug regimen that produces controlled, regulated hypothermia and avoids activating counterregulatory responses would likely be of clinical utility Tupone et al., 2014) .
The hypothermic effect of adenosine was first reported in 1931 (Bennet and Drury, 1931) . Once multiple adenosine receptor (AR) subtypes were identified, the hypothermia was attributed to action at A 1 AR, likely within the brain (Anderson et al., 1994) . Peripheral dosing of N 6 -cyclohexyladenosine (CHA; see Fig. S1 for structures) elicited hypothermia, which was lost in A 1 AR knock out (Adora1 À/À ) mice (Johansson et al., 2001) . CHA also caused hypothermia when infused directly into the nucleus of the solitary tract in rats (Tupone et al., 2013) . However, some data suggested a contribution from non-A 1 AR mechanisms, as only partial attenuation of hypothermia caused by N 6 -R-phenylisopropyladenosine (R-PIA) was seen in Adora1 À/À mice (Yang et al., 2007) .
More recently, it has become clear that adenosine agonists also induce hypothermia in mice via A 3 AR. A critical observation was that hypothermia caused by R-PIA was attenuated in A 3 AR knock out (Adora3 À/À ) mice (Yang et al., 2010) . In rodents, A 3 AR is expressed on immune cells (Borea et al., 2015) and A 3 AR agonists trigger mast cell degranulation (Auchampach et al., 1997; Fozard et al., 1996; Salvatore et al., 2000) . We have recently shown that A 3 AR agonists activate peripheral mast cells releasing histamine, which then acts on central histamine H 1 receptors to lower the Tb set point (Carlin et al., 2016) . Adenosine 5 0 -monophosphate (AMP) is a proposed natural regulator of torpor and injection of a large dose of AMP (500e3500 mg/kg, i. p.) causes hypothermia (Zhang et al., 2006) . Given the dose size, one might consider if some of the effects of AMP are due to its conversion to free adenosine (Rittiner et al., 2012; Swoap et al., 2007) . The observation that AMP's hypothermic effects remain intact in mice lacking any one of the four AR subtypes, indicates that AMP is not acting non-redundantly via a single AR (Daniels et al., 2010) . However, AMP-induced hypothermia was reported to be blocked by infusion of an A 1 AR antagonist in the pre-optic area (Muzzi et al., 2013) . The mechanism by which AMP causes hypothermia is currently unclear.
While studying hypothermia caused by A 3 AR agonists, we observed that some nucleoside derivatives commonly used as A 1 AR agonists also had activity at the A 3 AR. This prompted the current reexamination and comparison of A 1 AR agonists, A 3 AR agonists, and AMP. Our data suggest that each of these can trigger hypothermia in mice via different mechanisms.
Materials and methods

Mice
Male C57BL/6J and Kit WÀsh/WÀsh mice (Stock #012861) (Grimbaldeston et al., 2005; Nigrovic et al., 2008) were obtained from the Jackson Laboratory. Adora1 À/À mice on a C57BL/6J background were provided by Dr. Jurgen Schnermann (Sun et al., 2001) and genotyped by PCR (Adora1 reverse common primer 5 0 -ACATGGGGGTTGAACAGAGA, Adora1 forward primer 5 0 -AGCTGGC-TACCGCTACACAT, and Neo forward primer 5 0 -TCTGGATTCATC-GACTGTGG), producing 302 bp wild type and~900 bp null allele products. Adora3 À/À mice on a C57BL/6 background made by Merck (Salvatore et al., 2000) were provided by Dr. Stephen Tilley and genotyped by PCR (Adora3 reverse common primer 5 0 -ACTGGCC-CATACACAACCTG, Adora3 forward primer 5 0 -AGACAATGAAATA-GACGGTGGTG, and Neo forward primer 5 0 -ATGGAAGGATTGGAGCTACG), producing 208 bp wild type and~400 bp null allele products. Mice were singly housed at~22 C with a 12:12-h light-dark cycle. Chow (NIH-07, Envigo Inc, Madison, WI) and water were available ad libitum. Mice were studied !7 days after any operation or prior treatment. Reuse of mice tends to reduce physical activity levels, presumably due to acclimatization. No specific effort was made to acclimatize mice to handling in individual experiments. Studies were approved by the Animal Care and Use Committee of National Institute of Diabetes and Digestive and Kidney Diseases.
Drugs
The following compounds (vehicle) were purchased from Sigma (St. Louis, MO) or Tocris (Minneapolis, MN): Cl-ENBA, (±)-5'-chloro-5'-deoxy-N 6 -endo-norbornyladenosine (Franchetti et al., 2009; Trivedi et al., 1989 ) (10% DMSO in saline); CHA, N 6 -cyclohexyladenosine (dissolved in DMSO, then diluted to 10% DMSO with saline); CPA, N 6 -cyclopentyladenosine (saline); pyrilamine (saline); AMP, adenosine 5'-monophosphate (saline); CCPA, 2-chloro-N 6 -cyclopentyladenosine. MRS5474, (1R,2R,3S,5S)-4-(2-chloro-6-((dicyclopropylmethyl)amino)-9H-purin-9-yl)bicyclo [3.1.0]hexane-2,3-diol, (dissolved in DMSO, then diluted with 9 vol 30% PEG400) was synthesized as described (Tosh et al., 2012b) .
Adenosine receptor binding affinities
Binding affinity for mouse A 1 AR, A 2A AR, and A 3 ARs was measured as described 
Central infusions
Mice were anesthetized with ketamine/xylazine (80/10 mg/kg, i.p.). Sterile guide cannulas (5.25 mm, 26 gauge, Plastics One, Roanoke, VA) were unilaterally implanted into the lateral ventricle (coordinates relative to bregma: À0.34 mm anterior, 1.0 mm lateral, and þ1.7 mm ventral) and fixed with dental cement (Parkell, Edgewood, NY). Compounds in 5 ml were infused (0.5 ml/min) through a 33 gauge cannula protruding 0.5 mm past the tip of the guide cannula using PE-50 tubing fitted to a 5 ml syringe (Hamilton, Reno, NV). Cannula positions were verified by postmortem histological analysis.
Body temperature and activity telemetry and indirect calorimetry
Tb and activity were measured continuously by telemetry (Starr Life Sciences, Oakmont, PA) using ER4000 energizer/receivers, G2 E-mitters implanted intraperitoneally, and VitalView software with data collected each minute. Invalid E-mitter data points (defined as a change of !1 C in 1 min) were replaced by interpolation using flanking data. Any Tb 24 C were scored as 24 C. Unless noted otherwise, the average Tb response was calculated using the first 60 min after agonist dosing. Hypothermia duration is the duration of the interval between dosing and 300 min during which core temperature is < 35 C. Activity is the sum of counts from 10 to 60 min after A 1 AR agonist administration. Inhibitors were dosed 15 min before agonists. Indirect calorimetry was performed as described (Carlin et al., 2016) . Experiments were performed at 22 C. Occasionally a mouse did not become hypothermic with a treatment that generally caused hypothermia. In these cases, the same mouse was retested !7 days later and routinely became hypothermic and the second data set was used.
Temperature gradient
Environmental temperature preference was measured using an in-house apparatus by continuous video monitoring of the position of the mouse in a 45 cm thermal gradient, nominally 15 Ce35 C (Carlin et al., 2016) . Data are reported as mean ± SEM. Significance (two-tailed p < 0.05) was determined by t-test or ANOVA followed by post hoc Holm-Sidak multiple comparison tests.
Results
CHA induces hypothermia via both A 1 AR and A 3 AR
We investigated the ability of systemically-dosed adenosine agonists to cause hypothermia. CHA is~290-fold selective for binding to mouse A 1 AR over A 3 AR (Table 1) . With vehicle treatment, dosing-associated handling caused an increase in Tb and activity that lasted about an hour. Treatment of C57BL/6J mice with CHA (0.02e0.2 mg/kg, i.p.) caused a drop in Tb, accompanied by reduced physical activity (Fig. 1AeE) . The Tb and physical activity decrease and the increase in duration of hypothermia were all dose-dependent.
The in vivo specificity of CHA was examined using Adora1 À/À and Adora3 À/À mice. Hypothermia elicited by CHA (0.05 mg/kg, i.p.) was attenuated in both Adora1 À/À and Adora3 À/À mice, but was completely lost in Adora1
;Adora3 À/À double knock out mice (Fig. 1FeK ). These data demonstrate that the hypothermic effect of this low dose of CHA is contributed by agonism at both A 1 AR and A 3 AR.
MRS5474 induces hypothermia via A 3 AR
Truncated nucleoside MRS5474, which contains a bicyclic substitute for ribose, is a moderately selective, full A 1 AR agonist that is well tolerated in vivo (Tosh et al., 2012b ) and is~280-fold selective for binding to mouse A 1 AR over A 3 AR (Table 1) CPA is another widely used adenosine agonist with better selectivity (~2400-fold) for binding to mouse A 1 AR over A 3 AR (Table 1) . CPA caused a dose-dependent (0.03e3 mg/kg, i.p.) hypothermia and reduction in physical activity in C57BL/6J mice (Figs. S3A and B and data not shown). However, hypothermia induced by CPA (0.3 mg/kg, i.p.) was not significantly attenuated in Adora1 À/À mice and was attenuated but still present in Adora3
). These data suggest that the hypothermic effects of this dose of CPA are via agonism at A 3 AR, likely with a lesser contribution from A 1 AR. A related agonist, CCPA, is often used as a more selective A 1 AR agonist. However, we found that its binding affinity at the A 3 AR would make it even less desirable than CPA for use in mouse (Table 1 ). In general, there is a need to reexamine the affinities of widely used AR ligand probes across species (Alnouri et al., 2015) . Therefore, we compared the affinities of various agonists and antagonists at human and mouse receptors. Some previous studies of adenosine and hypothermia used DPCPX as a selective antagonist of the A 1 AR. However, the selectivity ratios of DPCPX vary significantly between species (Table 1 and (Alnouri et al., 2015) ).
In vivo Cl-ENBA is a more selective A 1 AR agonist
Cl-ENBA is the most selective A 1 AR agonist described, with 2600-fold selectivity for binding to human A 1 AR vs. A 3 AR (Franchetti et al., 2009; Trivedi et al., 1989) and~10,000-fold selectivity for mouse A 1 AR over A 3 AR (Table 1) . Cl-ENBA (0.3e10 mg/kg, i.p.) caused dose-dependent hypothermia and hypoactivity ( Fig. 2A, B and data not shown). Cl-ENBA (3 mg/kg, i.p.) hypothermia was not affected by pretreatment with raclopride (1 mg/kg, i.p.; data not shown). It was largely abolished in Adora1 À/ À mice ( Fig. 2C and D) , remained present in Adora3 ¡/¡ mice ( Fig. 2E and F), and was completely lost in Adora1 À/À ;Adora3 À/À mice ( Fig. 2G and H ). These data (and see 3.5) demonstrate that the hypothermic effects of Cl-ENBA are mainly mediated via A 1 AR, but at higher doses there is probably also a contribution from A 3 AR.
3.5. A 1 AR agonist-induced hypothermia occurs via central sites, while A 3 AR agonist-mediated hypothermia requires mast cells
The poor in vivo A 1 AR selectivity of systemic CHA and CPA prompted us to re-examine the role of mast cells and histamine in A 1 AR and A 3 AR agonist-induced hypothermia. Hypothermia from A 3 AR agonists is caused by histamine release from activated mast cells (Carlin et al., 2016) , while a role for mast cells in A 1 AR agonistinduced hypothermia has not been reported. Hypothermia from systemic Cl-ENBA at a dose of 1 mg/kg was largely intact in mast cell-deficient Kit WÀsh/WÀsh mice ( Fig. 3A and B) , while the hypothermia with 3 mg/kg was significantly attenuated (Fig. 3C and D) . In contrast, the hypothermic effect of MRS5474, at a dose that is selective for A 3 AR, was abolished in Kit WÀsh/WÀsh mice ( Fig. 3E and   F ). Pyrilamine, an histamine H 1 R antagonist, inhibited hypothermia from this dose, but did not block A 1 AR agonist-induced hypothermia (Figs. S4AeD) . These results show that, in contrast to A 3 ARmediated hypothermia, A 1 AR hypothermia does not require mast cells or H 1 R, and suggest that Cl-ENBA at 1 mg/kg i.p., but not 3 mg/ kg, is relatively selective for A 1 AR. We next examined the site of A 1 AR agonist action to induce hypothermia. Cl-ENBA infused intracerebroventricularly (i.c.v.) at 3.4 mg/mouse (~0.12 mg/kg) caused a drop in Tb comparable to 1 mg/kg given systemically ( Fig. 4A and B) . The effect of i.c.v. Cl-ENBA was greatly diminished in Adora1 À/À mice ( Fig. 4C and D) .
These results indicate that Cl-ENBA is acting via central A 1 AR. To avoid confounding due to the modest in vivo receptor specificity of the A 1 AR agonists, we used Adora3 À/À mice to investigate mechanistic aspects of A 1 AR-driven hypothermia. Cl-ENBA administration reduced metabolic rate and physical activity before the Tb nadir (Fig. 5AeC) . Additionally, Adora3 À/À mice treated with Cl-ENBA had a modest preference for a cooler place in a thermal gradient (Fig. 5DeG) . These results suggest that there is a reduced Tb set point and coordinated physiologic response to an A 1 AR agonist.
Neither A 1 AR nor A 3 AR is necessary for fasting-induced torpor
To better understand the role of adenosine in thermal physiology, baseline Tb and physical activity in light and dark phase were measured in Adora1 À/À , Adora3
, and Adora1 À/À ;Adora3 À/À mice.
There were no clear differences between littermate control and
;Adora3 ¡/¡ and agematched C57BL/6J mice (Fig. 6AeF) . A 24-h fast elicited torpor in both Adora1 ¡/¡ and Adora3 ¡/¡ mice (Fig. 6GeH) . In a test for receptor redundancy between A 1 AR and A 3 AR, Adora1
double knockout mice were found to enter fasting-induced hypothermia (Fig. 6I ). These data demonstrate that neither A 1 AR nor A 3 AR, individually or in combination, is required for fastinginduced torpor.
3.7. AMP does not require A 1 AR or A 3 AR to induce hypothermia and can act centrally
Large AMP doses (500e3500 mg/kg, i.p.) induce torpor (Zhang et al., 2006) . We studied a modest dose (100 mg/kg, i.p.) to minimize possible effects of impurities or breakdown products. The AMP-induced hypothermia was intact in Adora1 ¡/¡ and Adora3 ¡/¡ mice (Fig. 7AeD) . It was also intact in Adora1 dose (100 mg/mouse,~3.3 mg/kg) induced a drop in Tb that was comparable to a 30-fold larger (100 mg/kg) systemic dose and the hypothermia was not attenuated in Adora1 ¡/¡ mice ( Fig. 8A and B ).
Mice treated with AMP (100 mg/kg, i.p.) demonstrated a drop in Table 1 Ligand binding affinity at adenosine receptors.
K i , nM (or % inhibition at 10 mM). Bold indicates a K i ! 100-fold lower than the other two receptors of the same species. Superscripts indicate the references for literature data (mouse, human). SEMs are included for experimental results. a . b (Tchilibon et al., 2005) . c Current results. d (Tosh et al., 2012b ). e (Tosh et al., 2012a) . f (Paoletta et al., 2013) . g (Tosh et al., 2014) . h (Alnouri et al., 2015) . i (Klotz et al., 1998) . j (Ferkany et al., 1986; Gao et al., 2003; Stone et al., 1988) . k (Franchetti et al., 2009 ). l (Liang et al., 2010) . m (Kumar et al., 2011) . n . metabolic rate that preceded the hypothermia (Fig. 9AeC) . We did not observe a clear change in ambient temperature preference at this dose (not shown). With a higher dose (300 mg/kg, i.p.), the mice generally moved to a cooler region of a thermal gradient and became immobile (Fig. 9DeG) . When AMP was administered centrally (100 mg/mouse,~3.3 mg/kg, i.c.v.), there was a similar movement toward cooler environmental temperature but without a significant drop in activity (Fig. 9HeK) . These findings are consistent with AMP acting in the brain to reduce the Tb set point.
Discussion
We demonstrate at least three distinct adenosine-related routes to trigger hypothermia in mice (Fig. S5 ): 1) activation of central A 1 AR, 2) peripheral mast cell activation by A 3 AR agonists, releasing histamine, which stimulates histamine H 1 receptors, and 3) a central AMP-mediated mechanism. Additionally, we report that some agonists commonly used as A 1 AR probes also activate A 3 AR in vivo.
Suboptimal in vivo A 1 AR agonist selectivity
Much understanding of adenosine physiology has been acquired with selective ligands (Fredholm, 2014) (Table 1) . CHA and CPA were developed to be selective for A 1 AR vs "A 2 AR" (Moos et al., 1985) . The subsequent identification of four ARs and the generation of receptor-ablated animals now permit improved dissection of the specific receptors mediating adenosine actions. To our initial À ;Adora3 À/À (DKO) mice. In FeK, data are mean ± SEM, n ¼ 5e10/group in a crossover design; every tenth SEM is shown in F, H, and J; *p < 0.05, ***p < 0.001.
surprise, CHA, MRS5474, and CPA all produced hypothermia via A 3 AR, despite their much higher affinity for A 1 AR over A 3 AR. This is presumably due to higher drug exposure at peripheral mast cell A 3 AR, with poor availability at brain A 1 AR. This is striking, with a 2000-fold advantage in binding affinity being nullified by pharmacokinetic considerations. We did not measure peripheral A 1 AR effects of these agonists (eg., on heart rate, blood pressure, or kidney function (Sun et al., 2001; Vallon et al., 2006) ) for comparison with the peripheral mast cell A 3 AR effect. This observation suggests a reexamination of prior in vivo studies using CHA and CPA as A 1 AR probes. In mice, CHA is typically used at i. p. doses of 0.2e1 mg/kg, with ED 50 s in locomotor assays of 0.3e1.7 mg/kg (Akula and Kulkarni, 2014; Heffner et al., 1989; Zarrindast et al., 1993) . Doses of 0.1e1 mg/kg are reported in other species (Jinka et al., 2010 (Jinka et al., , 2015 Olson et al., 2013) . We demonstrate that both A 1 AR and A 3 AR contribute to hypothermia at a CHA dose of 0.05 mg/kg. Similarly, CPA is typically used in mice at doses of 0.2e1 mg/kg i.p., with ED 50 s in locomotor assays of 1.0e1.7 mg/kg (El Yacoubi et al., 2000; Heffner et al., 1989; Listos et al., 2011; Von Lubitz et al., 1993) . Comparable doses (0.1e1 mg/ kg) are used in rats (Heurteaux et al., 1995; O'Neill et al., 2014; Ramos-Zepeda and Herrero, 2013) . Our results with 0.3 mg/kg show that both A 1 AR and A 3 AR contribute to CHA-induced hypothermia. Thus, commonly used i.p. doses of both CPA and CHA stimulate both A 1 AR and A 3 AR and some effects attributed to A 1 AR may actually be due completely, or in part, to A 3 AR. This is of particular concern when the pharmacodynamic effect requires brain-penetration for an A 1 AR ligand but only peripheral exposure for A 3 AR. A non-brain penetrant agonist, SPA, was found to be highly selective for the mouse A 1 AR (~3000-fold vs A 3 AR) and could be useful in future in vivo studies.
There have been clinical trials of A 1 AR agonists for conditions such as diabetic foot pain, diabetes, glaucoma, and cardiac arrhythmias, many of which have failed (Elzein and Zablocki, 2008) . Other envisioned therapeutic applications of A 1 AR agonists are based on reported neuroprotective, antiseizure, anti-nociceptive, sleep promoting, and antidepressant effects (Tosh et al., 2012b) . The fact that some in vivo actions of agonists, that appear selective in in vitro receptor assays, also might include A 3 AR effects, should be considered in future development of such agonists. A 3 AR agonists display some similar effects, such as neuroprotection and antinociception (Janes et al., 2016) , which might contribute to efficacy of nominal A 1 AR agonists and would be difficult to separate mechanistically in clinical trials. The A 3 AR is expressed at relatively low levels in the mouse hippocampus, cerebellum and medulla (Janes et al., 2016; Yaar et al., 2005) . Thus, although we found no effects of centrally administered A 3 AR agonists on Tb, there may be effects of this receptor on CNS function. Cl-ENBA is a more selective A 1 AR agonist than CPA, CHA, and MRS5474 in the mouse for binding (Franchetti et al., 2009; Trivedi et al., 1989) (Table 1 ) and in vivo hypothermia. At 1 mg/kg i.p., Cl-ENBA was largely selective for A 1 AR, although at 3 mg/kg some of the effect was contributed by A 3 AR. Cl-ENBA is anti-nociceptive in the mouse at 0.5 mg/kg (Luongo et al., 2012) , suggesting that this effect is via A 1 AR. Cl-ENBA's greater selectivity makes it a preferred agonist for investigating in vivo A 1 AR physiology, at least in mice.
The Adora1 À/À and Adora3 À/À mice were essential for assessing in vivo ligand selectivity. In the absence of sufficiently selective A 1 AR agonists, using Adora3 À/À mice eliminates confounding A 3 AR effects. Adenosine agonist affinities and selectivities can vary profoundly among species (Table 1) (Alnouri et al., 2015) . Adenosine physiology can also vary by species-for example, A 3 AR is not present in some human mast cells (Rudich et al., 2012) . In summary, the results particularly suggest caution when studying in vivo effects of A 1 AR when using i.p. dosing.
A 3 AR hypothermia
A 3 AR agonists activate peripheral mast cells, releasing histamine, which then acts on central histamine H 1 receptors to lower the Tb set point (Carlin et al., 2016) . Here we examined the hypothermic effects of MRS5474 (Tosh et al., 2012b) and found that at 3 mg/kg i.p., MRS5474 is acting via A 3 AR. The hypothermia is lost in Kit WÀsh/WÀsh mice, confirming that A 3 AR agonism is acting via mast cells. Since histamine is reported to both increase and decrease Tb (Tabarean, 2016) , further study is required. The kinetics of hypothermia induction via A 3 AR and A 1 AR are similar, despite the peripheral vs central sites of agonist action. The likely explanation is that heat loss (and thus hypothermia) occurs slowly compared to the rapid increase in circulating histamine and quick neural transmission.
A 1 AR and regulated hypothermia
The poor in vivo A 1 AR selectivity of peripherally-dosed agonists raises concern that some physiology attributed to A 1 AR might actually be due to A 3 AR. For hypothermia, the lack of a Tb effect by brain A 3 AR agonist indicates that studies using central agonist dosing are probably studying A 1 AR effects. Thus, the hypothermia elicited by local CHA delivery to the anterior hypothalamus of Syrian hamsters or to the nucleus of the solitary tract of rats (Tupone et al., 2013) remain plausibly attributed to A 1 AR. A recent rat study used brain-penetrant CHA to produce A 1 AR hypothermia combined with a non-brain-penetrant antagonist (8-(p-sulfophenyl)theophylline) to block peripheral A 1 AR-mediated bradycardia (Jinka et al., 2015) . We interpret this experiment as additionally having hypothermia from peripheral CHA activation of rat mast cell A 3 AR (Fozard et al., 1996) , which may not be blocked by 8-(p-sulfophenyl)theophylline (Gao et al., 2001 ).
AMP hypothermia
Circadian fluctuation of plasma AMP concentration is a proposed endogenous regulator of torpor in rodents (Zhang et al., 2006) . Large exogenous doses of AMP (500e3500 mg/kg) cause torpor and have protective effects in various injury models (Miao et al, 2012 (Miao et al, , 2015 Tao et al., 2011; Wang et al., 2014) . There is no clearly identified receptor for AMP (although AMP has been proposed to be an A 1 AR ligand (Rittiner et al., 2012) ). In our studies, AMP-induced hypothermia did not require mast cells, A 1 AR, A 3 AR, H 1 R, D 2 R-like, or a combination of A 1 AR/A 3 AR. Other nucleotides, such as ATP, ADP and cyclic-AMP, have hypothermic effects when injected into the hypothalamic region in cats (Dascombe and Milton, 1975) , although the mechanisms have not been defined.
Proposed mechanisms for AMP-induced hypometabolism are that AMP uptake into erythrocytes causes increased 2,3-bisphosphoglycerate levels and reduced oxygen transport (Daniels et al., 2010) and/or that the AMP activates an intracellular energy depletion sensor, AMP-kinase (Melvin and Andrews, 2009 ). The observation that metabolic rate reduction precedes the drop in Tb (Daniels et al., 2010) and our results that relatively small amounts of i.c.v. AMP elicit hypothermia and AMP-treated mice chose a cool environment, all indicate that AMP acts centrally to reduce the Tb set point, suggesting direct or indirect action at the hypothalamus. Muzzi et al. have shown that AMP injected into the mouse preoptic area induces hypothermia and that AMP reduces firing activity of preoptic area neurons in a DPCPX-sensitive manner (Muzzi et al., 2013) . These observations and the Adora1À/ À data can be reconciled by hypothesizing that AMP causes hypothermia via both A 1 AR-dependent and A 1 AR-independent mechanisms.
Fasting-induced hypothermia does not require A 1 AR or A 3 AR
Mice have a large surface area/volume ratio and therefore a disproportionally high energetic cost of staying warm, so they enter torpor to conserve energy (Abreu-Vieira et al., 2015; Hudson and Scott, 1979; Swoap, 2008) . It is likely that the control of torpor is complex, integrating information on nutritional status, energy needs, and environmental situation. For example, leptin deficiency sensitizes to induction of torpor, but replacement of leptin in adipose-deficient mice does not prevent fasting-induced torpor (Gavrilova et al., 1999; Himms-Hagen, 1985) . There is much support for A 1 AR having a central role in regulating torpor, including daily torpor in mice (Iliff and Swoap, 2012) , seasonal torpor in arctic ground squirrel (Jinka et al., 2011) , and hibernation in Syrian hamsters . These conclusions are based on pharmacologic manipulation, showing torpor induction with agonist and exit with antagonist treatment. However, the observation that mice lacking A 1 AR (or A 3 AR, or both) enter torpor upon fasting demonstrates that A 1 AR is not required. However, due to the intrinsic variability of fasting-induced hypothermia and the size of our dataset, we cannot rule out quantitative or probabilistic effects of A 1 AR and/or A 3 AR on this process. This . AMP-induced hypothermia is accompanied by a reduced metabolic rate and preference for a cooler environment. The effect of AMP (100 mg/kg, i.p.) or vehicle in C57BL/6J mice on (A) total energy expenditure (TEE), (B) Tb, and (C) physical activity in a calorimetry chamber. The TEE falls before Tb (nadir~40 min vs~60 min). Data are mean ± SEM, n ¼ 5/group. Position (D,E) and activity (F,G) of C57BL/6J mice treated with AMP (300 mg/kg, i.p.) or vehicle and placed in a thermal gradient. Position (H,I) and activity (J,K) of C57BL/6J mice treated with AMP (100 mg, i.c.v.) or vehicle and placed in a thermal gradient. Mean ± SEM, n ¼ 5e6/group, *p < 0.05, ***p < 0.001.
illustrates the utility of the knock out mice, highlights the limitations of purely pharmacologic approaches, and suggests searching for the other regulators of torpor-related states. Presumably, like leptin, A 1 AR signaling is one of multiple inputs that are integrated to cause entry into (or exit from) torpor.
Limitations
Hypothermia can vary with inter-experiment differences, particularly in duration (with larger standard errors at longer times after dosing). Possible contributing factors include mouse age, weight, and adiposity, acclimation to handling, season, environmental temperature, and the noise/activity level in the animal facility. To assure that this variability does not compromise the conclusions, we focus on the all-or-none effects and have not attempted to quantitate the fraction of a mixed effect that is due to A 1 AR versus A 3 AR.
While knockout mice are excellent probes of in vivo ligand specificity, compensation for receptor loss may occur. No compensatory changes in Adora1À/À or Adora3À/À mice have been described (Johansson et al., 2001; Salvatore et al., 2000) , but it is possible that undetected compensatory changes do occur. Importantly, there may also be redundant sites of action, for example AMP may act at both A 1 AR and other site(s).
4.7. Common themes in A 1 AR, A 3 AR, and AMP hypothermia A 1 AR and A 3 AR agonists and AMP all trigger a regulated hypothermia that is not inhibited by D 2 R antagonist. Yet the three act in different places in the body, with different ligands and ligand affinities. Extracellular adenosine (and AMP) can be thought of as indicators of physiologically unfavorable situations or 'extreme physiology' (Fredholm, 2014) . It would be advantageous for the body to be able to broadly sense many forms of pathology and funnel the signals to common response mechanisms such as hypothermia. The ability to go into torpor is a widely conserved behavior that reduces injury, conserves energy, and increases survival. Understanding the neural regulation of hypothermia will identify signaling pathways and may lead to improved pharmacologic approaches to hypothermia induction and maintenance in clinical practice.
